TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

BACKGROUND: Emergence of resistance to molecular targeted therapy constitutes a limitation to clinical benefits in cancer treatment. Cross-resistance commonly happens with chemotherapeutic agents but might not with targeted agents. METHODS: In the current study, TP53 wild-type cell lines with drugga...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chiao-En, Koay, Tsin Shue, Ho, Yi-Hsuan, Lovat, Penny, Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407233/
https://www.ncbi.nlm.nih.gov/pubmed/30899200
http://dx.doi.org/10.1186/s12935-019-0768-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407233/
https://www.ncbi.nlm.nih.gov/pubmed/30899200
http://dx.doi.org/10.1186/s12935-019-0768-3

Ejemplares similares